PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters in Austin, Texas and GMP-validated manufacturing facilities in San Antonio, Texas.  The location of our operations provides us with many potential strategic advantages, including proximity to world-class cancer institutions and researchers and the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas, or CPRIT.  Since being founded in 2008, CPRIT has awarded almost $2.5 billion in funds toward more than 1,500 grants for cancer prevention and academic/product development research.

We have two lead drug product candidates in our pipeline, RNL™ and DocePLUS™, being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals.  This diverse and experienced team is using our proprietary and versatile nanotechnology platform to reformulate and deliver U.S. FDA-approved chemotherapeutics and widely-used radiotherapeutics in Europe to provide meaningful benefits to patients and healthcare providers.  The platform also serves as the foundation and affords us the opportunity in the future to develop additional drugs for rare cancers.


We believe in the critical importance of discovering, developing, and delivering complex and innovative treatments for patients battling rare cancers.


We envision medicines that will drastically enhance clinical and economic outcomes for patients and providers and forever change the future of human health worldwide.


Our company values guide our beliefs, behaviors, and interactions.  

Our goal is to live out these values everyday, everywhere, and with everyone.


Reliability, responsibility, and taking ownership of our work.


Ability to quickly respond and adapt to internal and external changes without losing our momentum.


Welcome transparency and direct feedback from colleagues, partners, providers, and patients alike.


Possess ongoing curiosity and courage to boldly experiment and discover.


Consistently remain ethical and commit to always doing the right thing, no matter what.


Keep our passion for the patient forever at the forefront of all we do.



Promise to deliver exceptional results and continually strive to enhance our standards.


Focus on achievement, taking smart risks, and delivering exceptional results.



Treat everyone we come in contact with dignity and kindness.


Cultivate a culture that encourages collaboration and welcomes different perspectives.



Marc Hedrick, MD

President and CEO

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc.  Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.  Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).  Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.  Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.


Andrew Sims

Vice President and Chief Financial Officer

Andrew Sims is Vice President and Chief Financial Officer at PLUS THERAPEUTICS, Inc.  Mr. Sims arrives at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price. Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.


Russ Havranek

Vice President - Corporate Strategy and New Product Planning

Russ Havranek is the Vice President of Corporate Strategy and New Product Planning at PLUS THERAPEUTICS, Inc.  He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics Inc.  Mr. Havranek has 24 years of marketing, general management, and product development experience with major life science companies including Johnson & Johnson, Guidant Corporation (now Abbott), Genentech Inc. (now Roche), and Volcano Corporation (now Philips).  Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.


Cheri Rice

Vice President - Product Development

Cheri Rice is the Vice President of Product Development at PLUS THERAPEUTICS, Inc.  She previously served in the same role at Cytori Therapeutics Inc.  Prior to joining Cytori, she served as Vice President of Disposable Development for Volcano Corporation, a leading developer of intravascular ultrasound diagnostic equipment from June 2008 until May 2015. Prior to Volcano she worked her way up through the ranks at Abbott Vascular, ending her tenure as Manager of Process Development. She brings 27 years of Program Management and Engineering in experience to Plus Therapeutics. Ms. Rice has her bachelor’s degree in Mechanical Engineering from San Diego State University.


Gregory Stein, MD

Senior Vice President - Clinical Development

Dr. Gregory Stein is Senior Vice President of Clinical Development at PLUS THERAPEUTICS, Inc. Prior to joining PLUS, Dr. Stein was a founder and executive of a number of healthcare and biotechnology companies. Most recently he co-founded and served as Chief Executive Officer at Curtana Pharmaceuticals, which develops drugs for the treatment of glioblastoma and other brain cancers. Curtana was awarded funding from the Cancer Prevention and Research Institute of Texas. Prior to Curtana, Dr. Stein was also a founder and served as the Vice President, Operations and Medical Affairs at Sova Pharmaceuticals, Inc., a venture-backed company that developed therapies for sleep-related breathing disorders and neuropathic pain. In addition, Dr. Stein has held senior positions at Genoptix, Opus Pharmaceuticals and Uzima Bioscience.

Dr. Stein was formerly a board certified Emergency Medicine Physician and previously practiced in Chicago serving as the Assistant Medical Director of the department and Associate Emergency Medical Services Director for the regional EMS system.

Dr. Stein is a graduate of the accelerated program at the Ohio State University School of Medicine and completed his residency at the University of Illinois Affiliated Hospitals in Chicago. In addition, Dr. Stein has a MBA from The Rady School of Management at UC San Diego.


Kara Davis

Corporate Counsel


Richard Hawkins


Richard J. Hawkins joined us as Director in December 2007 and was appointed to serve as Chairman in January 2018. Mr. Hawkins is currently the CEO of Lumos Pharma, Inc., a start-up pharma company. Mr. Hawkins founded LabNow Inc., a diagnostic device company developing rapid, point-of-care, physician office-based diagnostic testing systems, and served Chairman and CEO from 2004 until October 2009. Mr. Hawkins previously founded and guided the growth of Pharmaco, a clinical drug development services company where he served as Chairman, President, and Chief Executive Officer. He is a founder of id2, a pharmaceutical and biotechnology research management company, Sensus Drug Development Corp., a biotechnology company that was sold to Pfizer, and Covance Biotechnology Services, and served as Chairman of the Board for LoopOne, Inc., a shipping and logistics software company. Mr. Hawkins holds a B.S. in biology from Ohio University.

Marc Hedrick, MD

President and CEO

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc.  Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.  Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).  Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.  Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.


An van Es-Johansson, MD


An van Es-Johansson joined our Board in January 2020. Dr. van Es-Johansson currently serves as the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance.  From 2005-2018, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Swedish Orphan Biovitrum AB (Sobi), an international specialty biopharmaceutical company focused on rare diseases.  Dr. van Es-Johansson has leadership experience within large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and BioStratum.  She currently serves on the Board of Directors at BioInvent International AB, Medivir AB, Agendia Inc., and Savara Inc.  Dr. van Es-Johansson received a M.D. from Erasmus University in Rotterdam, The Netherlands.

Greg Petersen


Greg Petersen has served on our Board since February 2020. Mr. Petersen is an accomplished Executive and Board member with more than 25 years of strategy, operations, finance and compliance leadership experience. His 10 years of Board of Directors experience includes his current roles as Compensation Committee Chair and Audit Committee member of PROS Holdings and as Audit Committee Chair of Mohawk Group Holdings. Mr. Petersen has served as Executive Vice Chairman of Diligent Corporation and as Chief Financial Officer of Lombardi Software and Activant Solutions (now part of Epicor). He has also held executive positions at American Airlines and other corporations. Mr. Petersen has a BA from Boston College and an MBA from Duke University’s Fuqua School of Business.

Robert Lenk, PhD


Robert Lenk joined our Board in March 2020. Dr. Lenk has over 35 years as pharmaceutical executive with deep expertise in nanoparticle drug development and drug formulation. He is currently President of Lenk Pharmaceuticals, a pharmaceuticals development consultant to multinational corporations and startups. Previously, Dr. Lenk has been Chief Scientific Officer of MediVector, Inc., President of the NanoWorks division of Luna Innovations, Inc., President & CEO of Therapeutics 2000, Inc. and Vice President of Research & Development at Argus Pharmaceuticals. Dr. Lenk was also Cofounder of The Liposome Co. and a Staff Fellow of the National Institute of Child Health and Human Development. He has a PhD and BS from the Massachusetts Institute of Technology and resides in Danville, Virginia.

Howard Clowes


Howard Clowes joined our Board in March 2020. A retired partner after nearly four decades at DLA Piper, a leading law firm, Mr. Clowes has served in leadership positions in the firm’s Corporate and Securities Practice, advising public and private companies on securities law, financing, Mergers and Acquisition and general corporate matters. At the law firm of Gray Cary Ware & Freidenrich LLP, which was acquired by DLA Piper, he served as a partner in the Corporate Group, member of the Executive Committee and managing partner of the Transactions Group. Mr. Clowes has a J.D. from the University of California, Berkeley (where he now serves as a Lecturer), and a BA from the University of California, Santa Barbara. A resident of the Bay Area, Mr. Clowes served as President, Board Member and Chair of the Strategic Planning and Search Committee of the Law Foundation of Silicon Valley.


Manish Aghi, MD PhD

Professor, Neurological Surgery, at the Weill Institute for Neurosciences at the University of California, San Francisco.

Dr. Manish Aghi is a neurosurgeon, scientist and current faculty member in the department of neurological surgery and graduate division of biomedical sciences, as well as a principal investigator in the Brain Tumor Research Center at UCSF. He completed his MD-PhD Program through the Medical Scientist Training Program at Harvard Medical School, followed by neurological surgery residency and postdoctoral training at Massachusetts General Hospital. Dr. Aghi serves as principal investigator on multiple industry sponsored and investigator-initiated Phase 1-2 clinical trials comparing immunotherapy versus anti-angiogenic therapy of recurrent glioblastoma, as well as investigating convection-enhanced delivery of oncolytic viruses and nanoliposomal chemotherapy to recurrent glioblastoma.

Nicholas Butowski, MD

Professor, Neurological Surgery and Director, Translational Research, Neuro-Oncology at the Weill Institute for Neurosciences at the University of California, San Francisco.

Dr. Butowski is a neuro-oncologist who specializes in brain tumors, neuroimaging, cognitive and rehabilitative neurology, and complementary therapies for neurological disorders. He is director of clinical services in neuro-oncology and a co-investigator of National Cancer Institute-supported North American Brain Tumor Consortium clinical trials. Dr. Butowski earned his medical degree at the University of Illinois at Chicago and completed a residency in neurology and a fellowship in neuro-oncology at UCSF. He is a member of the American Academy of Neurology, American Society of Clinical Oncology and Society for Neuro-oncology.

Russell Lonser, MD

Professor and Chair, Department of Neurological Surgery at The Ohio State University Wexner Medical Center.

Dr. Lonser is a professor and chair of the Department of Neurological Surgery at The Ohio State University Wexner Medical Center, and currently holds the Dardinger Family Chair in Neurosurgical Oncology. Previously, he was chief of the Surgical Neurology Branch at the National Institutes of Health. Dr. Lonser specializes in the resection of brain, spinal cord, pituitary and brainstem tumors. He is a director on the American Board of Neurological Surgeons, and was the head of the research subcommittee in Head, Neck and Spine Injury Committee for the National Football League. Dr. Lonser has served on the editorial boards of NEUROSURGERY, World Neurosurgery, Journal of Neurosurgery, PLoS One and Science Reports.

Alireza Mohammadi, MD

Neurosurgeon at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Mohammadi is a board-certified neurosurgeon who specializes in neurosurgical oncology including surgery and laser ablation of brain tumors as well as radiosurgery for brain and spine. He is currently practicing at Neurosurgery Department and the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic. Since 2014, Dr. Mohammadi has also served as an assistant professor in Neurological Surgery at the Cleveland Clinic Lerner College of Medicine. Dr. Mohammadi earned his medical degree from Tehran University School of Medicine in Tehran, Iran. After completing his residency in neurosurgery at Shohada Hospital, he went on to complete his fellowship in neuro-oncology surgery and his fellowships in radiosurgery at the Cleveland Clinic.

Michael Vogelbaum, MD PhD

Chief of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center.

Dr. Vogelbaum is an internationally known leader in neurosurgical oncology and distinguished investigator in laboratory research, translational and clinical trials in gliomas. He is currently Chief of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center. Dr. Vogelbaum is also the inventor of patented medical devices for delivering therapeutics directly to the brain and brain tumors, with the first of these devices having received U.S. Food and Drug Administration clearance. After completing his M.D. and Ph.D. (Biomedical Engineering) at the University of Virginia, Dr. Vogelbaum completed his residency in neurological surgery at Barnes-Jewish Hospital in St. Louis, Mo.


Powered by People, Equipment, Facilities, Suppliers

We have completed facility validations at our nanoparticle manufacturing facility located in San Antonio, Texas, USA.  The facility and processes are designed to comply with cGMP per FDA and EMA regulations to manufacture drug candidates for research, development, clinical, and commercial use. Upon approval of our drug product candidates, our manufacturing capabilities will include validated manufacturing processes for drug product as well as a quality assurance product release process with the ability to ultimately scale-up the process to meet increasing market demands. We believe our strategic investments in the analytical and manufacturing capabilities, including personnel from drug discovery through drug development, will allow us to advance our product candidates more rapidly.

Expertise gained in manufacturing RNL™ DocePLUS™, and DoxoPLUS™ may be applied to other formulations in the future, allowing us to further leverage our capabilities. Our San Antonio facility enables us to produce drug product in a cost-effective manner while retaining control over the process and timing. As needed, the use of a qualified Contract Manufacturing Organization may be utilized to perform various manufacturing processes as we deem appropriate to meet our operational objectives.

Our current principal suppliers for our business are LGM Pharma and ScinoPharm Taiwan, which supply our active pharmaceutical ingredients, or APIs, doxorubicin and docetaxel, respectively, as well as Lipoid, LLC and Dishman Netherlands, which supply us with other raw materials used in the manufacture of our DocePLUS™ and DoxoPLUS™ drug candidates, and Eurofins, Columbia who supplies testing support for all products.


Why Join Us?

At PLUS THERAPEUTICS our employees are dedicated to developing and delivering innovative nanomedicines to health care providers and their patients. Because we believe that each employee contributes directly to our growth and success, we strive to encourage both their professional and personal development.

We foster a work place culture in which our employees are respected and valued so that we may recruit and retain the best people for our innovative, fast-paced, and exciting business.

We are an equal opportunity employer dedicated to diversity and fairness in the work place and invites you to submit your resume.


There are no job openings at this time.


PLUS THERAPEUTICS strives to provide its team with a comprehensive, competitive, and flexible selection of benefits to build health, wealth, and quality of life.

Vacation (Paid Time Off - PTO)

Enjoy time off on us. A balanced work life increases productivity. PLUS THERAPEUTICS offers paid time off, to be used for vacation and and sick time, and eleven (11) paid holidays.


Healthy employees mean a healthy work force. We understand that a comprehensive health and wellness program is key to maintaining a healthy and positive staff. PLUS THERAPEUTICS offers health coverage including medical, dental, and vision insurance plan options. We also offer flexible spending accounts to help reserve pre-tax dollars for health needs.

Life Protection

PLUS THERAPEUTICS’ insurance plans provide peace of mind. Our benefits program includes basic and voluntary life insurance options, as well as short-term and long-term disability insurance plans to replace a portion of your income in the event of injury, illness, or death.

Retirement Planning

Reaching your retirement and savings goals is simplified through PLUS THERAPEUTICS’ 401(k) Retirement Savings Plan. The plan is a convenient way for our people to save for retirement and meet future financial goals.

Employee Assistance

Life can become overwhelming at times, but help is just a call or click away with our employee assistance program (E.A.P.). PLUS THERAPEUTICS’ E.A.P. is designed to provide counseling 24/7 for employees and their family members regarding a variety of issues in or outside the home, from financial advice to conflict resolution at no additional cost.